Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Epi-lasik in U.S. Army Personnel

This study has been completed.
Sponsor:
Information provided by:
Walter Reed Army Medical Center
ClinicalTrials.gov Identifier:
NCT00413517
First received: December 18, 2006
Last updated: July 15, 2010
Last verified: July 2010
  Purpose

The purpose of this study is to evaluate the safety and efficacy of Epi-Lasik in U.S. Army personnel who have naturally occurring myopia with or without astigmatism. The data from this control group will be collected in such a way as to be comparable to data sets from study groups undergoing wavefront guided PRK, conventional PRK, and related laser refractive surgery procedures.


Condition Intervention
Myopia
Procedure: Epi-Lasik

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Epi-lasik in U.S. Army Personnel

Further study details as provided by Walter Reed Army Medical Center:

Primary Outcome Measures:
  • Safety and efficacy of Epi-LASIK [ Time Frame: 12 months after procedure ]

Estimated Enrollment: 150
Study Start Date: November 2006
Study Completion Date: September 2009
Intervention Details:
    Procedure: Epi-Lasik
    A vision correcting surgery
  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Active duty US Army Soldiers eligible for care at WRAMC
  2. Male or female, of any race, and at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
  3. Manifest refractive spherical equivalent (MSE) of up to 6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00 D.
  4. Manifest refraction and LADARWave™ refractions must be within 1.00 D.
  5. Best spectacle corrected visual acuity of 20/20 or better in both eyes.
  6. Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
  7. Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian; mires should be regular.
  8. Subject must expect to be located in the greater Washington DC area for a 12 month period post-operatively.
  9. Consent of the subject's command (active duty) to participate in the study.
  10. Access to transportation to meet follow-up requirements

Exclusion Criteria:

  1. Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy. [Pregnancy and breastfeeding are contraindications to refractive surgery in general, including epi-lasik, whether participating in this study or not]
  2. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
  3. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
  4. Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity.
  5. Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline.
  6. Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye.
  7. History of recurrent erosions or epithelial basement dystrophy.
  8. Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
  9. Any physical or mental impairment that would preclude participation in any of the examinations.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413517

Locations
United States, District of Columbia
Walter Reed Army Medical Center, Center for Refractive Surgery
Washington, District of Columbia, United States, 20307
Sponsors and Collaborators
Walter Reed Army Medical Center
Investigators
Principal Investigator: KRAIG S. BOWER, MD Walter Reed Army Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00413517     History of Changes
Other Study ID Numbers: WRAMC WU # 06-23020
Study First Received: December 18, 2006
Last Updated: July 15, 2010
Health Authority: United States: Federal Government

Keywords provided by Walter Reed Army Medical Center:
Naturally occurring myopia with or without astigmatism

ClinicalTrials.gov processed this record on November 25, 2014